Deng Jianxin, Yan Fang, Tian Jinglun, Qiao Aijun, Yan Dewen
Department of Endocrinology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Health Science Center of Shenzhen University, Shenzhen Clinical Research Center for Metabolic Diseases, No. 3002, Sungang West Road, Futian District, Shenzhen, 518035, Guangdong Province, China.
Geriatric Diseases Institute of Chengdu, Center for Medicine Research and Translation, Chengdu Fifth People's Hospital, Chengdu, 611137, Sichuan Province, China.
Diabetol Metab Syndr. 2023 Mar 4;15(1):35. doi: 10.1186/s13098-023-00998-y.
Diabetic cardiomyopathy (DCM) is a serious cardiovascular complication and the leading cause of death in diabetic patients. Patients typically do not experience any symptoms and have normal systolic and diastolic cardiac functions in the early stages of DCM. Because the majority of cardiac tissue has already been destroyed by the time DCM is detected, research must be conducted on biomarkers for early DCM, early diagnosis of DCM patients, and early symptomatic management to minimize mortality rates among DCM patients. Most of the existing implemented clinical markers are not very specific for DCM, especially in the early stages of DCM. Recent studies have shown that a number of new novel markers, such as galactin-3 (Gal-3), adiponectin (APN), and irisin, have significant changes in the clinical course of the various stages of DCM, suggesting that we may have a positive effect on the identification of DCM. As a summary of the current state of knowledge regarding DCM biomarkers, this review aims to inspire new ideas for identifying clinical markers and related pathophysiologic mechanisms that could be used in the early diagnosis and treatment of DCM.
糖尿病性心肌病（DCM）是一种严重的心血管并发症，也是糖尿病患者死亡的主要原因。在DCM早期，患者通常没有任何症状，心脏收缩和舒张功能正常。由于在检测到DCM时，大部分心脏组织已经被破坏，因此必须对DCM早期生物标志物进行研究，以便对DCM患者进行早期诊断和早期症状管理，从而将DCM患者的死亡率降至最低。现有的大多数临床标志物对DCM的特异性不是很强，尤其是在DCM早期。最近的研究表明，一些新的标志物，如半乳糖凝集素-3（Gal-3）、脂联素（APN）和鸢尾素，在DCM各个阶段的临床过程中都有显著变化，这表明这些标志物可能对DCM的识别有积极作用。作为关于DCM生物标志物当前知识状态的总结，本综述旨在激发新的思路，以确定可用于DCM早期诊断和治疗的临床标志物及相关病理生理机制。
